Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
2020年11月16日 - 10:00PM
Retrophin Inc., (NASDAQ: RTRX) today announced that the Company has
changed its global corporate name to Travere Therapeutics, Inc.
This new name reflects the Company’s steadfast dedication to
helping people as they navigate life with rare disease, as well as
the forward momentum of its promising pipeline of potential
first-in-class therapeutic candidates. In conjunction with the name
change, the Company expects to begin trading under the new ticker
symbol "TVTX" on the Nasdaq Global Select Market at market open on
November 19, 2020.
“Over the last several years we have emboldened a
patient-inspired mindset in all aspects of our organization, and
championed our mission of identifying, developing and delivering
life changing therapies to people living with rare disease,” said
Eric Dube, Ph.D., chief executive officer of Travere Therapeutics.
“We developed this new name to reflect our commitment to forging
new paths with patients to deliver hope and innovation, and to
honor our remarkable evolution. As we enter an exciting period of
our journey led by the promising future of our pipeline of
potential first-in-class therapies, now is the right time to
transition to Travere Therapeutics.”
The name Travere (pronounced “truh-veer”) Therapeutics
represents the Company’s commitment to being a trusted partner to
patients and their communities as they face the ever-changing path
of living with rare disease. Its patient-inspired approach is
captured in its new tagline, “In rare for life,” which speaks to
the Company’s dedication to working with the rare disease community
to make a positive impact on the many aspects of patients’ lives,
beyond delivering life-changing treatments.
Travere Therapeutics is advancing therapeutic candidates for
rare disorders in nephrology, hepatology and metabolism; sponsoring
no-cost genetic testing aimed at improving the diagnostic odyssey
for children born with cholestasis; partnering with patient
advocacy organizations to meet the diverse needs of patients and
their families; and ensuring broad access and education for its
FDA-approved therapies.
The Company’s pipeline is led by sparsentan, which is being
investigated in pivotal Phase 3 clinical trials for rare kidney
diseases - focal segmental glomerulosclerosis (FSGS) and IgA
nephropathy (IgAN). The DUPLEX Study in FSGS and the PROTECT Study
in IgAN are both positioned for topline readouts from the
proteinuria endpoints next year. Travere Therapeutics recently
expanded its promising pipeline with the addition of OT-58, now
called TVT-058, an investigational human enzyme replacement therapy
in Phase 1/2 development for the treatment of classical
homocystinuria. Travere Therapeutics continues to partner with
leaders in patient advocacy and the National Institutes of Health
on early research in rare metabolic and hepatic conditions - NGLY1
deficiency and Alagille syndrome.
As part of its commitment to patient communities, Travere
Therapeutics supports the Children’s National Rare Disease
Institute’s efforts to improve access and establish global best
practices in diagnosing and treating rare diseases. It recognizes
the needs of caregivers by collaborating with the National
Organization of Rare Disorders to launch and support the Rare
Caregiver Respite Program.
The Company leads efforts to make health equity a priority,
particularly among those in underrepresented communities with rare
disease. Travere Therapeutics helped form and is a sponsor of the
Rare Disease Diversity Coalition, led by the Black Women’s Health
Imperative, to address disparities in the healthcare system, access
issues, education and affordability. In addition, it worked with
the EveryLife Foundation to create their first-ever Diversity
Inclusion Advocacy Fellowship for Rare Diseases.
Along with the new name, the Company has adopted a new logo and
changed its corporate website. Please visit www.travere.com to
learn more.
About Travere Therapeutics
At Travere Therapeutics we are in rare for life. We are a
biopharmaceutical company that comes together every day to help
patients, families and caregivers of all backgrounds as they
navigate life with a rare disease. On this path, we know the need
for treatment options is urgent – that is why our global team works
with the rare disease community to identify, develop and deliver
life-changing therapies. In pursuit of this mission, we
continuously seek to understand the diverse perspectives of rare
patients and to courageously forge new paths to make a difference
in their lives and provide hope – today and tomorrow. For more
information, visit travere.com
Forward Looking Statements
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. Without limiting the foregoing, these statements are often
identified by the words "may", "might", "believes", "thinks",
"anticipates", "plans", "expects", "intends" or similar
expressions. In addition, expressions of our strategies, intentions
or plans are also forward-looking statements. Such forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties, including factors that could delay, divert
or change any of them, and could cause actual outcomes and results
to differ materially from current expectations. No forward-looking
statement can be guaranteed. Among the factors that could cause
actual results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with the Company’s business and finances in general, success of its
commercial products as well as risks and uncertainties associated
with the Company's preclinical and clinical stage pipeline.
Specifically, the Company faces risks associated with market
acceptance of its commercial products including efficacy, safety,
price, reimbursement and benefit over competing therapies. The
risks and uncertainties the Company faces with respect to its
preclinical and clinical stage pipeline include risk that the
Company's clinical candidates will not be found to be safe or
effective and that current clinical trials will not proceed as
planned. Specifically, the Company faces the risk that the Phase 3
clinical trial of sparsentan in FSGS will not demonstrate that
sparsentan is safe or effective or serve as a basis for accelerated
approval of sparsentan as planned; risk that the Phase 3 clinical
trial of sparsentan in IgAN will not demonstrate that sparsentan is
safe or effective or serve as the basis for accelerated approval of
sparsentan as planned; and for each of its development programs,
risk associated with enrollment of clinical trials for rare
diseases and risk that ongoing clinical trials may not proceed on
expected timelines or may be delayed for safety, regulatory or
other reasons and risk that the product candidates will not be
approved for efficacy, safety, regulatory or other reasons. The
Company faces risk that it will be unable to raise additional
funding that may be required to complete development of any or all
of its product candidates; risk relating to the Company's
dependence on contractors for clinical drug supply and commercial
manufacturing; uncertainties relating to patent protection and
exclusivity periods and intellectual property rights of third
parties; risks associated with regulatory interactions; and risks
and uncertainties relating to competitive products, including
potential generic competition with certain of the Company’s
products, and technological changes that may limit demand for the
Company's products. You are cautioned not to place undue reliance
on these forward-looking statements as there are important factors
that could cause actual results to differ materially from those in
forward-looking statements, many of which are beyond our control.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Investors are referred to the full
discussion of risks and uncertainties as included in the Company's
most recent Form 10-Q, Form 10-K and other filings with the
Securities and Exchange Commission.
Contact:Chris Cline,
CFA
Senior Vice
President, Investor Relations & Corporate
Communications888-969-7879 IR@retrophin.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/77722810-42db-4d6f-b926-dda768e58504
Retrophin (NASDAQ:RTRX)
過去 株価チャート
から 8 2024 まで 9 2024
Retrophin (NASDAQ:RTRX)
過去 株価チャート
から 9 2023 まで 9 2024